Ameriprise Financial Inc. Has $225.08 Million Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Ameriprise Financial Inc. grew its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 20.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,827,658 shares of the specialty pharmaceutical company’s stock after purchasing an additional 315,608 shares during the quarter. Ameriprise Financial Inc. owned approximately 3.02% of Jazz Pharmaceuticals worth $225,076,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in JAZZ. Moloney Securities Asset Management LLC bought a new stake in Jazz Pharmaceuticals during the 4th quarter worth approximately $464,000. Franklin Resources Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 4.6% during the third quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company’s stock worth $124,208,000 after purchasing an additional 48,708 shares during the period. Hennion & Walsh Asset Management Inc. grew its stake in shares of Jazz Pharmaceuticals by 13.7% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 35,894 shares of the specialty pharmaceutical company’s stock worth $4,420,000 after purchasing an additional 4,332 shares during the last quarter. BTC Capital Management Inc. raised its position in Jazz Pharmaceuticals by 9.4% during the 4th quarter. BTC Capital Management Inc. now owns 49,653 shares of the specialty pharmaceutical company’s stock worth $6,115,000 after purchasing an additional 4,271 shares during the last quarter. Finally, Summit Trail Advisors LLC acquired a new position in Jazz Pharmaceuticals during the 4th quarter worth about $539,000. 89.14% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Stock Performance

NASDAQ JAZZ opened at $118.19 on Tuesday. The company has a market cap of $7.28 billion, a P/E ratio of 16.65, a PEG ratio of 1.04 and a beta of 0.38. The company has a fifty day simple moving average of $122.11 and a 200 day simple moving average of $122.54. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 12-month low of $95.49 and a 12-month high of $148.06.

Insider Activity

In related news, CMO Robert Iannone sold 7,080 shares of the company’s stock in a transaction on Friday, March 7th. The stock was sold at an average price of $138.60, for a total transaction of $981,288.00. Following the completion of the sale, the chief marketing officer now owns 82,024 shares in the company, valued at approximately $11,368,526.40. This represents a 7.95 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CAO Patricia Carr sold 4,813 shares of the firm’s stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $144.42, for a total value of $695,093.46. Following the transaction, the chief accounting officer now owns 8,237 shares in the company, valued at approximately $1,189,587.54. This trade represents a 36.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 28,236 shares of company stock worth $3,956,190 over the last three months. 4.20% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Barclays reissued an “overweight” rating and issued a $200.00 price target (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. HC Wainwright raised their price target on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a “buy” rating in a report on Monday, March 10th. Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $130.00 to $170.00 in a research note on Thursday, February 13th. Needham & Company LLC reissued a “buy” rating and set a $210.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, April 10th. Finally, Royal Bank of Canada cut their price target on shares of Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $187.71.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.